Nanoviricides to restart Ebola program

|By:, SA News Editor

NanoViricides (NYSEMKT:NNVC) announces that it will restart its Ebola drug development program in light of the persistent outbreak in West Africa. CEO Eugene Seymour, M.D., Ph.D, says, "We are happy to restart the Ebola program considering the public health impact of the Ebola virus infection. We are in a strong financial position now, enabling us to work on this project while we continue to advance our FluCide and DengueCide therapies further towards clinical trials. We hope to create highly effective drugs against Ebola similar to what we have achieved with our FluCide Influenza drug candidate."